Finding the ‘Guilty’ Gene Variant of Sporadic Parkinson’s Disease Via CRISPR/Cas9

被引:0
|
作者
Shenzhao Lu
Jiawei Zhou
机构
[1] Chinese Academy of Sciences,Institute of Neuroscience, State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences
来源
Neuroscience Bulletin | 2017年 / 33卷
关键词
Parkinson’s disease; Genetic variant; CRISPR/Cas9;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease (PD) is a common neurodegenerative disorder affecting millions of people worldwide, but its cause and pathogenesis are still not fully understood. Earlier studies have shown that SNCA, which encodes α-synuclein, is one of the key genes associated with PD. Single-nucleotide polymorphism (SNP) variants of SNCA are thought to be correlated with disease onset. The underlying mechanisms however are enigmatic. A recent study published in Nature revealed that one of the SNP variants in the SNCA non-coding element elevated α-synuclein expression in human neurons by reducing the binding efficiency of transcription factors, demonstrating a previously uncharted role for SNPs in the pathogenesis of PD.
引用
收藏
页码:115 / 117
页数:2
相关论文
共 50 条
  • [21] CRISPR/Cas9 gene editing therapies for cystic fibrosis
    Graham, Carina
    Hart, Stephen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (06) : 767 - 780
  • [22] CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease
    Rahman, Mujeeb Ur
    Bilal, Muhammad
    Shah, Junaid Ali
    Kaushik, Ajeet
    Teissedre, Pierre-Louis
    Kujawska, Malgorzata
    PHARMACEUTICS, 2022, 14 (06)
  • [23] Guidelines for optimized gene knockout using CRISPR/Cas9
    Van Campenhout, Claude
    Cabochette, Pauline
    Veillard, Anne-Clemence
    Laczik, Miklos
    Zelisko-Schmidt, Agnieszka
    Sabatel, Celine
    Dhainaut, Maxime
    Vanhollebeke, Benoit
    Gueydan, Cyril
    Kruys, Veronique
    BIOTECHNIQUES, 2019, 66 (06) : 295 - 302
  • [24] Therapeutic gene editing in haematological disorders with CRISPR/Cas9
    Jensen, Trine I.
    Axelgaard, Esben
    Bak, Rasmus O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 821 - 835
  • [25] Therapeutic applications of CRISPR/Cas9 system in gene therapy
    Hasan Mollanoori
    Shahram Teimourian
    Biotechnology Letters, 2018, 40 : 907 - 914
  • [26] Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy
    Wang, Le
    Zheng, Wenfu
    Liu, Shaoqin
    Li, Bing
    Jiang, Xingyu
    CHEMBIOCHEM, 2019, 20 (05) : 634 - 643
  • [27] A review of CRISPR Cas9 for ASCVD: treatment strategies and could target PSCK9 gene using CRISPR cas9 prevent the patient from atherosclerotic vascular disease?
    Suwito, Bambang Edi
    Adji, Arga Setyo
    Wardani, Vira Aulia Kusuma
    Widjaja, Jordan Steven
    Angel, Syalomitha Claudia Stefanie
    Rahman, Firman Suryadi
    BALI MEDICAL JOURNAL, 2022, 11 (02) : 985 - 993
  • [28] Therapeutic applications of CRISPR/Cas9 system in gene therapy
    Mollanoori, Hasan
    Teimourian, Shahram
    BIOTECHNOLOGY LETTERS, 2018, 40 (06) : 907 - 914
  • [29] Lipid and polymer mediated CRISPR/Cas9 gene editing
    Gong, Yan
    Tian, Siyu
    Xuan, Yang
    Zhang, Shubiao
    JOURNAL OF MATERIALS CHEMISTRY B, 2020, 8 (20) : 4369 - 4386
  • [30] Evolution of Resistance Against CRISPR/Cas9 Gene Drive
    Unckless, Robert L.
    Clark, Andrew G.
    Messer, Philipp W.
    GENETICS, 2017, 205 (02) : 827 - 841